Cat. No.: HY-117650A

RG7834

(Synonyms: RO 7020322; (S)-RO0321)

10 Cited Publications

Customer Review

Based on 10 publication(s) in Google Scholar

RG7834 (RO 7020322) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC₅₀s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells.

For research use only. We do not sell to patients.

Purity: 99.29%
CAS No.: 2072057-17-9
Formula: C₂₂H₂₇NO₆
Molecular Weight:401.45

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

RG7834 Chemical Structure

CAS No.: 2072057-17-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (10)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

IC50: 2.8 nM (HBsAg), 2.6 nM (HBeAg), 3.2 nM (HBV DNA)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2 2.2.15	CC₅₀	>10 μM Compound: 1; RG-7834	Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability measured after 4 days by CellTiter-Glo reagent based assay Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability measured after 4 days by CellTiter-Glo reagent based assay	[PMID: 34267883]
HepG2 2.2.15	CC₅₀	>50 μM Compound: (S)-64; RG7834	Cytotoxicity against human HepG2.2.15 cells by CCK-8 assay Cytotoxicity against human HepG2.2.15 cells by CCK-8 assay	[PMID: 30286292]
HepG2 2.2.15	EC₅₀	1.2 nM Compound: RG7834	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg level incubated for 6 days by microplate-based chemiluminescence immunoassay Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg level incubated for 6 days by microplate-based chemiluminescence immunoassay	[PMID: 38190324]
HepG2 2.2.15	IC₅₀	0.001 μM Compound: 1; RG7834	Inhibition HBsAg secretion in human HepG2.2.15 cells treated for 3 days followed by medium replacement without compound measured after 2 days by CLIA Inhibition HBsAg secretion in human HepG2.2.15 cells treated for 3 days followed by medium replacement without compound measured after 2 days by CLIA	[PMID: 38428537]

In Vitro

RG7834 ((S)-(+)-64) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC₅₀s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells^[1].
RG7834 has no activity against CYP3A4, CYP2D6, CYP2C9 (IC₅₀s >50 μM) or hERG channel^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

RG7834 (4 mg/kg, twice daily for 21 days) shows anti-HBV efficacy in HBV-infected human liver chimeric uPA-SCID mice^[1].
RG7834 (2, 14.5 mg/kg, p.o.) exhibits good oral bioavail ability, with a half-life of 4.9 h in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

HBV-infected human liver chimeric uPA-SCID mice^[1]
Dosage:

4 mg/kg
Administration:

Twice daily for 21 days
Result:

Reduced both HBsAg and HBeAg, also decreased serum HBV DNA by 0.6 log10 in mice.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 2072057-17-9
Appearance Solid
Molecular Weight 401.45
Formula C₂₂H₂₇NO₆
Color Light yellow to yellow
SMILES

O=C(O)C1=CN2[C@@H](CC3=CC(OCCCOC)=C(C=C3C2=CC1=O)OC)C(C)C
Synonyms

RO 7020322; (S)-RO0321
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (10)

All Cell Imaging/StainingBio/Physico-chemical AssayWBRT-PCR

Sort by:

Journal Impact Factor

Proc Natl Acad Sci U S A

RNA tailing machinery drives amyloidogenic phase transition. [Abstract]

2024 Jun 4;121(23):e2316734121. PMID: 38805292

RG7834 purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2024 Jun 4;121(23):e2316734121. [Abstract]

TENT4 inhibitor, RG7834 (1 μM; 1 h), impairs liquid-to-solid phase transition of Amyloid bodies. Numbers denote percentage of cells with intranucleolar foci.
Emerg Microbes Infect

Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection. [Abstract]

2021 Dec;10(1):37-50. PMID: 33296295
PLoS Pathog

Host species-specific mutations in the thumb domain of the 3Dpol polymerase are required for efficient replication of human hepatitis A virus in mice. [Abstract]

2026 May 11;22(5):e1014213. PMID: 42113844
Antiviral Res

Hepato-selective dihydroquinolizinones active against hepatitis A virus in vitro and in vivo. [Abstract]

2025 May:237:106145. PMID: 40118118
Antiviral Res

An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity. [Abstract]

2024 Jun:226:105888. PMID: 38641024
Microbiol Spectr

A visible assay for evaluating the inhibitory activity of drug and antibody against HBV infection. [Abstract]

2026 Apr 7;14(4):e0263825. PMID: 41810956
J Virol

A hepatitis B virus RNA-sensing and RNA-editing-dependent reporter system. [Abstract]

2025 Oct 10:e0092225. PMID: 41070966

RG7834 purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Oct 10:e0092225. [Abstract]

Activation of HBV-RADARS corresponds to its target HBV RNA levels in HepG2.2.15. The results showed that treating cells with the HBV RNA destabilizing compound RG7834 (1 μM) (except for HBx mRNA) significantly reduced total HBV RNA and antigen expression, corresponding with a decrease in HBV RNA-mediated Gluc activation from the HBV-RADARS reporter.
ACS Med Chem Lett

Hepatoselective Dihydroquinolizinone Bis-acids for HBsAg mRNA Degradation. [Abstract]

2021 Jun 22;12(7):1130-1136. PMID: 34267883
University of Colorado Denver

2024.
Research Square Preprint

2022 May.

RG7834 purchased from MedChemExpress. Usage Cited in: Research Square Preprint. 2022 May.

Telomere lengths determined by Southern blot TRF analysis of gDNA prepared from WT_iPSC_F and R449G_iPSC_1 treated with RG7834 (1 μM), Cordycepin, or DMSO. The results showed that RG7834 partially restored telomere length in R449G_iPSC_1 (lanes 7).

RG7834 purchased from MedChemExpress. Usage Cited in: Research Square Preprint. 2022 May.

Total RNA prepared from WT_iPSC_F and R449G_iPSC_1 cells treated with RG7834 (1 μM), Cordycepin, or DMSO was subjected to qRT–PCR for oligoadenylated hTR. Bar graph of the mean fold change relative to DMSO-treated samples and normalized to GAPDH, ATP5b, and HPRT. The results showed that RG7834 (1 μM) led to a decrease in the proportion of oligoadenylated hTR.

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (311.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4910 mL

12.4549 mL

24.9097 mL

5 mM

0.4982 mL

2.4910 mL

4.9819 mL

10 mM

0.2491 mL

1.2455 mL

2.4910 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.87 mg/mL (7.15 mM); Clear solution

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Han X, et al. Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action. J Med Chem. 2018 Oct 4. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4910 mL	12.4549 mL	24.9097 mL	62.2743 mL
	5 mM	0.4982 mL	2.4910 mL	4.9819 mL	12.4549 mL
	10 mM	0.2491 mL	1.2455 mL	2.4910 mL	6.2274 mL
	15 mM	0.1661 mL	0.8303 mL	1.6606 mL	4.1516 mL
	20 mM	0.1245 mL	0.6227 mL	1.2455 mL	3.1137 mL
	25 mM	0.0996 mL	0.4982 mL	0.9964 mL	2.4910 mL
	30 mM	0.0830 mL	0.4152 mL	0.8303 mL	2.0758 mL
	40 mM	0.0623 mL	0.3114 mL	0.6227 mL	1.5569 mL
	50 mM	0.0498 mL	0.2491 mL	0.4982 mL	1.2455 mL
	60 mM	0.0415 mL	0.2076 mL	0.4152 mL	1.0379 mL
	80 mM	0.0311 mL	0.1557 mL	0.3114 mL	0.7784 mL
	100 mM	0.0249 mL	0.1245 mL	0.2491 mL	0.6227 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

RG7834

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

Orally Active Compound Library

Highly Selective Inhibitors Library

MCE Bioactive Compound Library

Clinical Compound Library Plus

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) RG7834

Biological Activity

Chemical Information

Publications (10)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

RG7834

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

Orally Active Compound Library

Highly Selective Inhibitors Library

MCE Bioactive Compound Library

Clinical Compound Library Plus

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) RG7834

Biological Activity

Chemical Information

Publications (10)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

RG7834 Related Classifications

HY-117650A Related Classifications